EU Regulator Denies Approval for Alzheimer's Drug Lecanemab

The decision cites serious side effects despite the drug's potential to slow cognitive decline in early-stage patients.

The European Medicines Agency rejected lecanemab due to risks like brain swelling and bleeding.
The drug, known as Leqembi, had shown a 27% reduction in cognitive decline in trials.
Lecanemab is already approved in the US, Japan, South Korea, China, and Israel.
The UK's MHRA is still reviewing the drug, with a decision expected soon.
Experts and Alzheimer's organizations have expressed disappointment but remain hopeful for future treatments.